PRMT5 Inhibitors | Global Pipeline

Last Update: Nov 25, 2022

PRMT5 Inhibitors

Company Candidate MOA Indications Phase
JanssenJNJ-64619178SAM competitive AND peptide competitiveNHL, MDSI
Tango TherapeuticsTNG908MTA cooperative inhibitorMTAP-deleted cancersI
Mirati TherapeuticsMRTX9768PRMT5-MTA complex inhibitor, MTA competitiveMTAP deleted cancersI/Ib
AmgenAMG 193MTA cooperative inhibitorMTAP-deleted solid tumors +- docetaxelI
Eli LillyLLY-283Brain-penetrant SAM competitiveGliomasPreclin
Jubilant TherapeuticsJBI-778Brain-penetrant substrate competitive Glioblastoma, Brain metastases, MCLPreclin

Discontinued Programs

Company Candidate MOA Indications Phase
Prelude TherapeuticsPRT543SAM competitiveACC, HRD+ tumors (BRCA1/2) Myelofibrosis, MDSI
Prelude TherapeuticsPRT811Brain-penetrant SAM competitiveGBM, CNS lymphoma, CNS metastasesI
PfizerPF-06939999SAM competitiveNSCLC, HNSCC, esophageal, endometrial, cervical, bladder I
GSKGSK3326595 SAM uncompetitive, peptide competitiveMDS, AML, Advanced solid tumors (ACC)I
GSKGSK3368715SAM uncompetitive-Preclin